Scholarlink

Background <p>[<sup>68</sup>Ga]Ga-PentixaFor, a CXCR4-targeted PET tracer, has shown potential in multiple myeloma. However, [<sup>68</sup>Ga]Ga-PentixaFor-PET/CT acquisition protocols lack standardization. This is a prospective ancillary study to the PentiMyelo trial aimed to determine the optimal acquisition time for [<sup>68</sup>Ga]Ga-PentixaFor-PET.</p> Results <p>Twenty multiple myeloma patients underwent [<sup>68</sup>Ga]Ga-PentixaFor-PET/CT at 60&#xa0;min post-injection, with additional acquisitions at 30, 40, 50&#xa0;min (Group 1) or 75, 85, 95&#xa0;min (Group 2). Semi-quantitative metrics including SUV, tumor-to-background ratios and image noise — assessed by the coefficient of variation, were systematically analyzed. Physiological liver, spleen and mediastinal blood-pool uptakes decreased over time while image noise increased. A total of 343 lesions were detected (316 in Group 1, 27 in Group 2). Neither earlier nor later acquisition time affected the positivity of [<sup>68</sup>Ga]Ga-PentixaFor-PET, which was positive in 10 of 20 patients (5 in Group 1 and 5 in Group 2). In Group 1, tumor-to-background ratio was significantly higher at 60&#xa0;min; in Group 2, tumor-to-background ratio remained stable.</p> Conclusions <p>An acquisition time of 60&#xa0;min post-injection provided optimal lesion contrast, supporting its adoption as the standard imaging time point for [<sup>68</sup>Ga]Ga-PentixaFor-PET/CT.</p> Trial registration <p>Name of the registry: ClinicalTrials.gov. Trial registration number: NCT04561492. Date of registration: 17 September 2020. URL of trial registry record: <a href="https://clinicaltrials.gov/study/NCT04561492">https://clinicaltrials.gov/study/NCT04561492</a>. <i>This imaging sub-study is ancillary to the PentiMyelo prospective trial registered under the identifier NCT04561492.</i></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal acquisition time of [68Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Chloé François,
  • Thomas Carlier,
  • Cyrille Touzeau,
  • Anna Janz,
  • Constance Dubégny,
  • Bastien Jamet,
  • Françoise Kraeber-Bodéré,
  • Clément Bailly,
  • Caroline Bodet-Milin

摘要

Background

[68Ga]Ga-PentixaFor, a CXCR4-targeted PET tracer, has shown potential in multiple myeloma. However, [68Ga]Ga-PentixaFor-PET/CT acquisition protocols lack standardization. This is a prospective ancillary study to the PentiMyelo trial aimed to determine the optimal acquisition time for [68Ga]Ga-PentixaFor-PET.

Results

Twenty multiple myeloma patients underwent [68Ga]Ga-PentixaFor-PET/CT at 60 min post-injection, with additional acquisitions at 30, 40, 50 min (Group 1) or 75, 85, 95 min (Group 2). Semi-quantitative metrics including SUV, tumor-to-background ratios and image noise — assessed by the coefficient of variation, were systematically analyzed. Physiological liver, spleen and mediastinal blood-pool uptakes decreased over time while image noise increased. A total of 343 lesions were detected (316 in Group 1, 27 in Group 2). Neither earlier nor later acquisition time affected the positivity of [68Ga]Ga-PentixaFor-PET, which was positive in 10 of 20 patients (5 in Group 1 and 5 in Group 2). In Group 1, tumor-to-background ratio was significantly higher at 60 min; in Group 2, tumor-to-background ratio remained stable.

Conclusions

An acquisition time of 60 min post-injection provided optimal lesion contrast, supporting its adoption as the standard imaging time point for [68Ga]Ga-PentixaFor-PET/CT.

Trial registration

Name of the registry: ClinicalTrials.gov. Trial registration number: NCT04561492. Date of registration: 17 September 2020. URL of trial registry record: https://clinicaltrials.gov/study/NCT04561492. This imaging sub-study is ancillary to the PentiMyelo prospective trial registered under the identifier NCT04561492.